Binds Oligosaccharide Structure Patents (Class 530/387.5)
-
Patent number: 6663863Abstract: The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD18 or CCR2.Type: GrantFiled: March 15, 2001Date of Patent: December 16, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher J. Horvath, Patricia E. Rao
-
Patent number: 6638506Abstract: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using antibodies specific for Fc&ggr;RIII receptor. In one aspect, the antibody may be a monoclonal antibody. In another aspect, the antibody or the monoclonal antibody may be conjugated with a cytotoxic substance. In a further aspect, the antibody binds to the Fc&ggr;RIII receptor, inactivates the receptor, and destroys cellular forms containing the receptor.Type: GrantFiled: September 7, 1999Date of Patent: October 28, 2003Inventor: Walter Schubert
-
Patent number: 6627740Abstract: The present invention provides a monoclonal antibody which binds to a polypeptide as set forth in SEQ ID NO: 1 as described herein.Type: GrantFiled: August 24, 2001Date of Patent: September 30, 2003Inventors: Toshio Hirano, Tsuneyasu Kaisho
-
Patent number: 6627457Abstract: Methods for detecting pregnancy in a woman comprise screening a biological sample of the woman for pregnancy markers. The methods of the invention include chemiluminescent assays for the pregnancy markers. The methods of the invention also comprise utilizing at least two capture antibodies that specifically bind different epitopes of the pregnancy marker in one assay. The methods of the invention permit detection of pregnancy within about 7 days after ovulation or implantation.Type: GrantFiled: July 30, 2001Date of Patent: September 30, 2003Assignee: Quest Diagnostics Investments IncorporatedInventors: Murugan R. Pandian, Julie Y. Lu
-
Patent number: 6613327Abstract: Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated costimulatory signal in a T cell such that spontaneous abortion in the subject is inhibited. The subject methods are also based on the levels of adhesion molecules, inflammatory cytokines, and immune cell surface molecules which are altered in spontaneous abortion.Type: GrantFiled: July 28, 2000Date of Patent: September 2, 2003Assignee: Genetics Institute, Inc.Inventors: Vincent Ling, Gary S. Gray, James C. Keith, Srinivas Maganti
-
Patent number: 6596689Abstract: A class of proteoglycans containing fucosylated acidic glycans, e.g., as produced by marine sponges and sea urchin embryos, have been found to stimulate selective proliferation of mammalian natural killer (NK) cells and &ggr;&dgr;T cells. These compounds are useful as pharmaceuticals, particularly as immunostimulants, e.g., in the treatment of cancer and viral infections.Type: GrantFiled: December 6, 2000Date of Patent: July 22, 2003Inventor: Gradimir Misevic
-
Patent number: 6596277Abstract: The present invention provides substantially pure integrins containing a novel &bgr; subunit designated as &bgr;6. The novel &bgr;6 subunit forms heterodimers with &agr;V and &agr;F. Methods of controlling cell adhesion using the &bgr;6-containing integrins are also provided.Type: GrantFiled: February 6, 2002Date of Patent: July 22, 2003Assignee: The Regents of the University of CaliforniaInventors: Dean Sheppard, Robert Pytela
-
Patent number: 6586524Abstract: The present invention relates to cationic polymeric conjugates and methods of preparing and using them as gene carriers. The cationic polymeric conjugates comprise a poly(ethylene glycol) (PEG) grafted cationic polymer and a targeting moiety(TM), wherein 0.1 to 10 mole percent of the cationic groups of the cationic polymer are substituted with PEG-TM.Type: GrantFiled: July 19, 2001Date of Patent: July 1, 2003Assignee: Expression Genetics, Inc.Inventor: Kazuyoshi Sagara
-
Patent number: 6576427Abstract: Nucleic acid sequences for HC gp-39L is provided. Methods of detecting altered expression of tissue remodeling proteins and diagnosing tissue remodeling disorders are also provided.Type: GrantFiled: May 2, 1997Date of Patent: June 10, 2003Assignee: SmithKline Beecham CorporationInventors: Robert B Kirkpatrick, Martin Rosenberg
-
Patent number: 6573055Abstract: Polyclonal antibodies can be produced that reacts with recombinant EPO and its degradation products but not with native EPO. This antibody precipitation can be used to identify those glycopeptides that are uniquely reactive. These glycopeptides can be produced on preparative scale and used in the production of monoclonal antibodies which are screened against the original EPO and glycopeptides to select antibodies reactive to the specific glycopeptides an recombinant EPO but not to native human EPO. The monoclonal antibodies so selected are incorporated in a conventional ELISA and used to monitor urine and other bodily samples taken from athletes, either human or animal, and patients for presence and level of recombinant peptides or proteins. Alternatively, the polyclonal antibody can be used directly to produce ELISA tests.Type: GrantFiled: April 21, 1998Date of Patent: June 3, 2003Assignee: Glycozyme, Inc.Inventor: Allen K. Murray
-
Patent number: 6569431Abstract: The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences derived from combinatorial phage display libraries selected for high-affinity binding to myelin oligodendrocyte glycoprotein.Type: GrantFiled: July 5, 2001Date of Patent: May 27, 2003Assignee: The Regents of the University of CaliforniaInventors: Hans-Christian von Büdingen, Claude P. Genain, Stephen L. Hauser
-
Patent number: 6551599Abstract: The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of Campylobacter jejuni (Cj) only and (2) epitopes conserved between Campylobacter jejuni and Campylobacter coli (Cc) outer membranes; to specific monoclonal antibodies made by the methods of the instant invention; and uses thereof The invention is drawn further to immunogens comprising the outer membrane complexes of Cj and Cc.Type: GrantFiled: March 16, 2001Date of Patent: April 22, 2003Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Robert E. Mandrell, Anna H. Bates, David L. Brandon
-
Patent number: 6537553Abstract: The present invention provides antagonists to cell adhesion useful in controlling the negative effects of inflammation, and the metastasis of cancer cells. These antagonists are ligands to E-selectin containing the sialyl Lex structure, including sialyl Lex glycoproteins, sialyl Lex glycolipids, and sialyl Lex oligsaccharides, and other related sialyl Lex-containing molecules capable of inhibiting E-selectin mediated cell adhesion to endothelial cells. The present invention also provides antibodies against sialyl Lex determinants capable of interrupting E-selectin mediated cell adhesion, which are also considered antagonists according to the present invention. The present invention also provides methods of using the antagonists of the present invention to reduce inflammation, and methods to inhibit the process of metastasis by carcinogenic cells.Type: GrantFiled: January 6, 1995Date of Patent: March 25, 2003Assignee: La Jolla Cancer Research FoundationInventors: Minoru Fukuda, Ritsuko Sawada, Shigeru Tsuboi
-
Patent number: 6514497Abstract: Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.Type: GrantFiled: October 1, 1998Date of Patent: February 4, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Lily Zou
-
Patent number: 6500627Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: February 3, 1998Date of Patent: December 31, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 6492337Abstract: The use of glycolipids, in particular galactosylceramide, glucosylceramide and lactosylceramide, and specific catchers therefor (antibodies or lectins), in particular monoclonal antibodies, for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications in an individual and for use in the production of pharmaceutical preparations for treatment of said conditions is disclosed.Type: GrantFiled: September 21, 2000Date of Patent: December 10, 2002Assignee: A+ Science ABInventors: Pam Fredman, Karsten Buschard
-
Patent number: 6488929Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: GrantFiled: July 12, 1999Date of Patent: December 3, 2002Assignee: Montana State UniversityInventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Patent number: 6482602Abstract: Reagents and methods for the detection of Staphylococcus aureus are provided. The reagents contain an antibody that binds to a capsular polysaccharide of type 5 of Staphylococcus aureus, and can be used in methods for detection of oxacillin resistant Staphylococcus aureus that escapes detection by agglutination in the presence of fibrinogen and antibodies directed against protein A of Staphylococcus.Type: GrantFiled: August 8, 2000Date of Patent: November 19, 2002Assignee: Institut PasteurInventors: Jean-Michel Fournier, Alain Boutonnier
-
Patent number: 6458934Abstract: The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.Type: GrantFiled: November 12, 1999Date of Patent: October 1, 2002Assignee: LG Chemical LimitedInventors: Hyo Jeong Hong, Sung Sup Park, Young Jun Kang, Chang-Yuil Kang, Sung Kwan Yoon
-
Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
Patent number: 6432402Abstract: The present invention provides an anti-idiotypic monoclonal antibody which specifically induces an immune response against a glycosphingolipid. Additionally, this invention provides a method of producing the anti-idiotypic monoclonal antibody. Finally, this invention provides a composition of matter comprising an effective amount of a cytokine and a melanoma ganglioside-specific antibody attached to a carrier.Type: GrantFiled: May 23, 1995Date of Patent: August 13, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Paul B. Chapman, Alan N. Houghton -
Patent number: 6429295Abstract: The present invention is related with the field of immunology and human medicine, particularly with the generation and selection of a monoclonal antibody (Mab) that recognizes the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tumors. One of the objectives of this invention is to provide a Mab of the IgG1 type that has the characteristic of recognizing with high specificity N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tissues of breast, melanomas and tumors of the liver, stomach, colon, rectum and kidneys. It also has the capacity of producing direct cytolysis of the tumoral cells bearing the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence, thus can be used for the diagnosis and treatment of certain neoplasic diseases.Type: GrantFiled: November 22, 1999Date of Patent: August 6, 2002Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Adriana Carr Pérez, Zaima Mazorra Herrera, Luis Enrique Fernández Molina, Ana Maria Vázquez López, Ailette Mulet Sierra, Rolando Pérez Rodríguez
-
Publication number: 20020086012Abstract: A soluble bispecific fusion protein consisting of a) a binding domain which recognizes a specific surface molecule on a target cell, covalently linked to b) a domain capable of stimulating T cell proliferation, can be used for a specific costimulation of a T cell directed against said target cell.Type: ApplicationFiled: August 31, 1999Publication date: July 4, 2002Inventors: WINFRIED WELS, BERNHARD GERSTMAYER
-
Patent number: 6391635Abstract: Disclosed herein are method for producing hydridoma cell lines producing monoclonal human natural IgM antibodies and hybridoma cells produced by the methods. The antibodies are the monoclonal equivalents of circulating human natural antibodies.Type: GrantFiled: May 23, 2000Date of Patent: May 21, 2002Assignee: Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 6391301Abstract: The present invention relates to a novel composition for identifying and suppressing the growth of tumor cells, which comprises antibodies which react with proteins having N-glycosidically bonded saccharides.Type: GrantFiled: August 16, 1999Date of Patent: May 21, 2002Assignee: Forschungszentrum Karlsruhe GmbHInventors: Jonathan Sleeman, Helmut Ponta, Peter Herrlich, Kim Untae
-
Publication number: 20020028202Abstract: The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients with such antibodies.Type: ApplicationFiled: April 2, 2001Publication date: March 7, 2002Inventors: Linda C. Burkly, Christopher D. Benjamin, Catherine Hession, Adrian Whitty
-
Patent number: 6350449Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 1999Date of Patent: February 26, 2002Assignee: Baxter International Inc.Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6340743Abstract: Antibody ligands are provided for specific binding to the stalk of a polymeric immunoglobulin receptor (plgr) of a cell with the proviso that the ligand does not substantially bind to secretory component of plgR under physiological conditions. The ligand may be targeted to, into, or across the cell and may comprise a biologically active composition.Type: GrantFiled: December 30, 1999Date of Patent: January 22, 2002Assignee: The Regents of the University of CaliforniaInventors: Keith E. Mostov, Janice Richman-Eisenstat
-
Patent number: 6309639Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.Type: GrantFiled: August 9, 2000Date of Patent: October 30, 2001Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
-
Patent number: 6287789Abstract: The subject invention provides methods and kits for detecting increased bone resorption in patients. These methods and kits use chondroitin sulfate, a glycosaminoglycan, as a marker for bone resorption. Levels of chondroitin sulfate are detected in samples of urine or serum taken from patients. Measurements of chondroitin sulfate levels are made by methods such as fluorophore-assisted carbohydrate electrophoresis (FACE). Knowledge of increased bone resorption rates is useful in diagnosis of bone disorders such as osteoporosis.Type: GrantFiled: February 8, 1999Date of Patent: September 11, 2001Assignee: BioMarin PharmaceuticalsInventor: John C. Klock
-
Patent number: 6287568Abstract: This invention includes the conception of T-independent conjugate-vaccines and its application in the induction of antigen specific IgA response. We demonstrated that 1) &agr;(1,6)dextran can elicit a markedly enhanced IgA response in T-cell free mice (20-50 fold higher than in normal mice); 2)co-injection of the molecule with other antigens can enhance the IgA response to the co-antigen; and 3)a dextran-Gag conjugate can elicit the Gag-specific IgA. Thus, the invention identified &agr;(1,6)dextran as a carrier molecule for producing the T-independent conjugates and as an adjuvant for the enhancement of IgA production. The T-independent property of these conjugates makes it especially useful in vaccinations against HIV and other infectious and non-infectious diseases associated with T-cell deficiency.Type: GrantFiled: September 9, 1998Date of Patent: September 11, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: Denong Wang, Bernard F. Erlanger, Elvin A. Kabat
-
Publication number: 20010010926Abstract: The invention concerns a new immunoregulatory protein LST-1, nucleic acid sequences coding for this protein, a process for the isolation of this protein, as well as its use for the production of a therapeutic agent. The DNA and protein sequences are shown in SEQ ID NO; 1 to 4.Type: ApplicationFiled: December 18, 1997Publication date: August 2, 2001Applicant: ROCHE DIAGNOSTICS GMBHInventor: ELIZABETH WEISS
-
Patent number: 6228599Abstract: Antibodies specific to pectin, specifically to homogalacuronin capable of recognizing a certain motif on the pectin structure were produced. These antibodies can be used alone or linked to a detectable moiety. They can be used in an assay or can be used to produce a food.Type: GrantFiled: February 26, 1999Date of Patent: May 8, 2001Assignee: Danisco A/SInventors: John Paul Knox, William George Tycho Willats, Jorn Dalgaard Mikkelsen
-
Patent number: 6204366Abstract: A reshaped human antibody or reshaped human antibody fragment having specificity for human polymorphic epithelial mucin (PEM) is produced by transferring the complementarity determining regions (CDRS) from a murine anti-HMFG hybridoma cell line HMFG1 into a human antibody variable region framework. The reshaped molecule can be used in the treatment or diagnosis of cancer.Type: GrantFiled: May 7, 1993Date of Patent: March 20, 2001Assignee: Unilever Patent Holdings B.V.Inventor: Martine Elisa Verhoeyen
-
Patent number: 6190863Abstract: The present invention is directed to a sugar-chain-recognizing antibody which belongs to the IgM isotype and which recognizes Gg4Cer(Gal&bgr;1-3GalNAc&bgr;1-4Gal&bgr;1-4Glc&bgr;Cer) or GM2 which appears on HIV infected cells, as well as to a therapeutics for HIV diseases containing those IgMs.Type: GrantFiled: May 19, 1998Date of Patent: February 20, 2001Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Hidechika Okada, Noriko Okada
-
Patent number: RE37596Abstract: The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cell lines for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic, aid, active substance or active substance carrier.Type: GrantFiled: June 16, 1999Date of Patent: March 19, 2002Assignee: Dade Behring Marburg GmbHInventors: Klaus Bosslet, Bernhard Auerbach, Helmut Peters